Health Care/Hospital
Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO
HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The ...
2023-10-24 20:00
1110
Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval
SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "BioRay") announced onOctober 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration (FDA). This marks BioRay's first ...
2023-10-24 15:05
1073
OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product
Visit OBiO at ESGCT 30th Annual Congress in Brussels SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene...
2023-10-24 12:05
1296
Wingderm® Has Unveiled the Latest Research of Mesoskin for Mesotherapy Treatment at AMWC
BEIJING, Oct. 23, 2023 /PRNewswire/ -- On October 20-22, 2023, the Aesthetic & Anti-Aging Medicine World Congress (AMWC) was held inChengdu, China. A wide range of aesthetic plastic surgery products and technologies made their appearance at this event, Wingderm®'s Latest Research of Mesoskin for ...
2023-10-24 09:23
1120
A Safer Tomorrow: AESOP Technology's Battle Against Look-Alike, Sound-Alike Medication Errors
SAN FRANCISCO, Oct. 23, 2023 /PRNewswire/ -- Medication errors are a critical
problem in healthcare, and Look-Alike, Sound-Alike (LASA) medication errors
pose a particularly daunting challenge. Studies
2023-10-24 00:03
1184
Genesis MedTech initiates enrollment in its North American Early Feasibility Study using the J-Valve™ Transfemoral System for patients with severe aortic regurgitation
BURLINGAME, Calif., Oct. 23, 2023 /PRNewswire/ -- Genesis MedTech, a leading medical device company, today announced initiation of enrollment in its North American Early Feasibility Study using its dedicated TAVR system, J-Valve™ Transfemoral (TF) System. The procedure was successfully perform...
2023-10-23 22:00
1450
Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis
MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ...
2023-10-23 21:30
1185
WAT Medical Donates to the Canadian Red Cross and Peach Arch Hospital
VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- WAT Medical Enterprise Ltd. has
extended its support to two prominent institutions: the Canadian Red Cross and
Peach Arch Hospital, throughmonetary donations.
2023-10-23 21:00
1246
AI Diagnostic Platform Company Noul, unveils the result of Malaria study in Ethiopia and Ghana
* Reaffirming innovation as an AI-based digital microscope while presenting new malaria data at the annual meeting of the ASTMH 2023 * Noul's 'miLab™' showed significantly higher sensitivity than that of microscopy in health centers YONGIN, South Korea, Oct. 23, 2023 /PRNewswire/ -- Noul Co.,...
2023-10-23 21:00
1331
COSMAX NBT Showcases Exclusive Materials and Formulations at SSW 2023, Strengthening its Presence in the U.S. Market
* Display microemulsion technology and plant-based formulation * Various exclusive materials prepared for skin health, wrinkles, and even hair health SEONGNAM, South Korea, Oct. 23, 2023 /PRNewswire/ -- COSMAX NBT, a global leading supplements ODM (original development manufacturing) company, ...
2023-10-23 21:00
1595
VUNO Secures FDA 510(k) Clearance for VUNO Med®-DeepBrain®
SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ -- VUNO Inc., South Korean
medical AI company has received 510(k) clearance from the Food and Drug
Administration (FDA) for its AI-powered brain quantification device, VUNO
Med®-DeepBrain®.
2023-10-23 21:00
1272
Zhongchao Inc. Launches Breast Cancer Follow-up Visit and Health Management Patient Guide Program on Breast Cancer Awareness Day
SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that its Zhongxin platform launched a WeChat mini program of Bre...
2023-10-23 20:00
1173
Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC
SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest clinical data of it...
2023-10-23 19:56
1130
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs
SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces the latest clinical progress of 2 novel drugs including Nectin-4 ADC 9MW2821, as well as the clinical study data to be reported on ESMO 2023. Latest progress...
2023-10-23 18:25
1248
JINGHAO MEDICAL's self-fitting OTC hearing aids received FDA 510(k) approval
HONGKONG, SHANGHAI, and BEIJING, Oct. 23, 2023 /PRNewswire/ -- As the first hearing aid manufacturer to be listed in China, JINGHAO MEDICAL has once again taken a historic step. OnSeptember 26, 2023, the self-fitting OTC hearing aid developed and manufactured by JINGHAO MEDICAL officially receive...
2023-10-23 18:01
1158
Global Healthcare Accreditation Welcomes Karin Jay as President of Global Strategy and Announces Renée-Marie Stephano's Transition to CEO
New Leadership Aims to Reinforce GHA's Position as the Foremost Authority in Medical and Well-being Travel Accreditation PALM BEACH GARDENS, Fla., Oct. 23, 2023 /PRNewswire/ -- Global Healthcare Accreditation (GHA), the esteemed authority in accreditation and certification with a specialized foc...
2023-10-23 18:00
1456
Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients
* Sunvozertinib monotherapy demonstrated superior efficacy and excellent safety in patients in the 1st line setting for advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins) mutations, achieving a confirmed objective...
2023-10-23 17:34
1082
InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023
NANJING, China, Oct 22, 2023 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome drug resistance for hard-to-treat solid tumors, announces that clinical data of Ifebemtinib (IN10018), a highly potent and selective oral i...
2023-10-23 08:00
1414
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO
* The ORR (objective response rate) and the DCR (disease control rate) in the frontline setting of glecirasib (KRAS G12C Inhibitor) in combination with JAB-3312 (SHP2 inhibitor) were 65.5% (38/58) and 100% respectively in all dose groups of advanced non-small cell lung cancer (NSCLC), among whi...
2023-10-22 15:05
1812
Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA - A Potassium Ion Channel Opener for Amyotrophic Lateral Sclerosis
SHANGHAI, Oct. 20, 2023 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced that one of its innovative small-molecule KCNQ2/3 selective opener compounds (CB03), developed for the treatment of amyotrophic lateral sclerosis (ALS), received orphan drug designation (ODD) from US F...
2023-10-20 21:00
1031
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
8263
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
6458
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
6406
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
6176
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
6139
